These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27566252)

  • 1. Genomic alterations in neuroendocrine cancers of the ovary.
    Yaghmour G; Prouet P; Wiedower E; Jamy OH; Feldman R; Chandler JC; Pandey M; Martin MG
    J Ovarian Res; 2016 Aug; 9(1):52. PubMed ID: 27566252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
    McCullar B; Pandey M; Yaghmour G; Hare F; Patel K; Stein K; Feldman R; Chandler JC; Martin MG
    Breast Cancer Res Treat; 2016 Jul; 158(1):195-202. PubMed ID: 27329168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-based Analysis of the Clinical Features of Primary Small Cell Carcinoma of the Ovary.
    Jamy O; Yaghmour G; Hare F; Martin MG
    Anticancer Res; 2015 May; 35(5):3091-5. PubMed ID: 25964600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of molecular targets in vulvar cancers.
    Palisoul ML; Mullen MM; Feldman R; Thaker PH
    Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small Cell Carcinoma of the Ovary: Clinicopathologic and Immunohistochemical Analysis of 7 New Cases of a Rare Malignancy.
    Gupta P; Kapatia G; Gupta N; Dey P; Rohilla M; Gupta A; Rai B; Suri V; Rajwanshi A; Srinivasan R
    Int J Surg Pathol; 2021 May; 29(3):236-245. PubMed ID: 32772748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer: A retrospective observational cohort study.
    Hu D; Ma D; Zhang ZJ; Zhang Y; Huang K; Li X
    Front Endocrinol (Lausanne); 2023; 14():1103429. PubMed ID: 36742399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
    Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
    Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
    Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.
    Weiss GJ; Byron SA; Aldrich J; Sangal A; Barilla H; Kiefer JA; Carpten JD; Craig DW; Whitsett TG
    PLoS One; 2017; 12(6):e0179170. PubMed ID: 28586388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma.
    Cooke SL; Ennis D; Evers L; Dowson S; Chan MY; Paul J; Hirschowitz L; Glasspool RM; Singh N; Bell S; Day E; Kochman A; Wilkinson N; Beer P; Martin S; Millan D; Biankin AV; McNeish IA;
    Clin Cancer Res; 2017 Dec; 23(24):7633-7640. PubMed ID: 28954785
    [No Abstract]   [Full Text] [Related]  

  • 14. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond
    Auguste A; Blanc-Durand F; Deloger M; Le Formal A; Bareja R; Wilkes DC; Richon C; Brunn B; Caron O; Devouassoux-Shisheboran M; Gouy S; Morice P; Bentivegna E; Sboner A; Elemento O; Rubin MA; Pautier P; Genestie C; Cyrta J; Leary A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32575483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT).
    Lang JD; Hendricks WPD
    Methods Mol Biol; 2018; 1706():367-379. PubMed ID: 29423809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
    Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
    J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
    Mahdi H; Xiu J; Reddy SK; DeBernardo R
    J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung.
    Miyoshi T; Umemura S; Matsumura Y; Mimaki S; Tada S; Makinoshima H; Ishii G; Udagawa H; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Aokage K; Hishida T; Yoshida J; Nagai K; Goto K; Tsuboi M; Tsuchihara K
    Clin Cancer Res; 2017 Feb; 23(3):757-765. PubMed ID: 27507618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.